Merck sends HPV vax to FDA

Share this article:
Merck adds heat to HCV competition
Merck adds heat to HCV competition

Merck upped the HPV vaccination race Thursday, filing the biologics license application for its nine-valent Human Papillomavirus vaccine.

The drugmaker currently manufacturers Gardasil, which protects against four types of HPV, a virus that causes just about every form of cervical cancer and is known to cause oropharyngeal cancer, which is cancer that affects the soft palate, tongue and tonsils. GlaxoSmithKline also makes an HPV vaccine, but it protects against fewer versions of the virus.

Although the R&D emphasis on all forms of cancer, particularly the recent push in immuno-oncology treatments, could make a vaccine that prevents cancer seem like a welcome achievement, recent research from the Centers for Disease Control and Prevention indicates that the prevention-over-cure angle is not resonating with parents, a key demographic, because pre-teens are the target vaccination audience.

Among the CDC's findings: vaccination rates among girls are around 33%, far below a goal of 80%. While these figures reflect US rates, studies show common misconceptions about the vaccine keep parents from vaccinating girls across geographies: mainly, the assumption that vaccination will lead to unchecked sexual activity. These same studies have shown that vaccination has not increased sexual activity among vaccinated girls.

The vaccination rate among boys is lower, but rising: the Advisory Committee on Immunization Practices recommended making the vaccine a routine part of boys' healthcare in 2011.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...